Adverum Biotechnologies to Participate in Upcoming Investor Conferences
21 Septiembre 2023 - 3:05PM
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage
company that aims to establish gene therapy as a new standard of
care for highly prevalent ocular diseases, today announced that
Adverum Biotechnologies will present at the following upcoming
investor conferences:
- Cantor Fitzgerald Global Healthcare Conference 2023 on
Thursday, September 28, 2023 at 8:00 a.m. ET.
- Chardan’s 7th Annual Genetics Medicines Conference on Monday,
October 2, 2023 at 10:00 a.m. ET.
The on-demand webcast corporate presentation may be accessed
under Events and Presentations in the Investors section of
Adverum’s website. A replay of the webcast will be available on the
website for 90 days following the presentation.
About Adverum BiotechnologiesAdverum
Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that
aims to establish gene therapy as a new standard of care for highly
prevalent ocular diseases with the aspiration of developing
functional cures to restore vision and prevent blindness.
Leveraging the capabilities of its proprietary intravitreal (IVT)
platform, Adverum is developing durable, single-administration
therapies, designed to be delivered in physicians’ offices, to
eliminate the need for frequent ocular injections to treat these
diseases. Adverum is evaluating its novel gene therapy
candidate, ixoberogene soroparvovec (Ixo-vec, formerly
referred to as ADVM-022), as a one-time, IVT injection for patients
with neovascular or wet age-related macular degeneration.
Additionally, by overcoming the challenges associated with current
treatment paradigms for debilitating ocular diseases, Adverum
aspires to transform the standard of care, preserve vision, and
create a profound societal impact around the globe. For more
information, please visit www.adverum.com.
Corporate, Investor and Media Inquiries
Adverum Biotechnologies, Inc.E: ir@adverum.com
Adverum Biotechnologies (NASDAQ:ADVM)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Gráfica de Acción Histórica
De May 2023 a May 2024